AHA Scientific Sessions Offers Outstanding Late-Breaking Science

From a AHA email I received.  You will notice there is not one session on stroke rehabilitation or prevention of neuronal cascade of death. Scientific Sessions will again offer the latest science via its popular Late-Breaking Clinical Trials. Attendees will have the opportunity to hear 28 LBCTs. These presentations are selected based on their unique approach to the topic, their design methods and the overall quality of the statistical plan. In addition, 19 trials will be presented in the format of Clinical Science: Special Report sessions and will focus on registries, updates to existing trials and important clinical science.

The following presentations are scheduled, as of Aug. 13, 2012. LBCTs Practice Implications for CAD and VTE Aspirin for the Prevention of Recurrent Venous Thromboembolism After a First Unprovoked Event: Results of the ASPIRE Randomized Controlled Trial A Randomized Trial of Bedside Platelet Function Monitoring to Adjust Antiplatelet Therapy Versus Standard of Care in Patients Undergoing Drug Eluting Stent Implantation: The ARCTIC Study First Large-Scale Platelet Function Evaluation in an Acute Coronary Syndromes Trial--The TRILOGY ACS Platelet Function Sub-study Results of the Trial to Assess Chelation Therapy Main Results of the Future REvascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease (FREEDOM) Trial Health Economics and Quality of Life in Contemporary Trials Prospective Evaluation of Outcomes With Stress Perfusion Imaging Versus Stress Wall Motion Imaging During Dobutamine or Exercise Echocardiography Economic Outcomes of Percutaneous Coronary Intervention Performed at Sites With and Without On-Site Cardiac Surgery Quality of Life Outcomes in the Trial to Assess Chelation Therapy (TACT) Cost-Effectiveness of PCI With Drug Eluting Stents Versus Bypass Surgery for Patients with Diabetes and Multi-vessel Coronary Artery Disease: Results from the FREEDOM Trial Treatments for Prevention of Cardiovascular Events: A Population Perspective Omega-3 Fatty Acids for the Prevention of Recurrent Symptomatic Atrial Fibrillation: Results of a Double-Blind Randomized Clinical Trial (FORWARD) (NCT00597220) Fish Oil for the Prevention of Post-Operative Atrial Fibrillation--The Omega-3 Fatty Acids for Prevention of Post-Operative Atrial Fibrillation (OPERA) Trial A Randomized Trial of a Multivitamin in the Prevention of Cardiovascular Disease in Men: The Physicians' Health Study II Use of a Multidrug Pill In Reducing cardiovascular Events (UMPIRE) Novel Treatments for Managing Lipid Disorders Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD): Interim Results From a Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Goal Achievement after Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects (GAUSS): Interim Results From a Randomized, Double-Blind, Placebo-Controlled Study Effects of 12 Weeks of Treatment with RN316 (PF-04950615), a Humanized IgG2Δa Monoclonal Antibody Binding Proprotein Convertase Subtilisin Kexin Type 9, in Hypercholesterolemic Subjects on High and Maximal Dose Statins CaPre®, A Novel Class of Omega-3-Phospholipids, Therapy in Patients With Mild-to-High Hypertriglyceridemia (From The Multicenter Placebo-Controlled, Randomized, Double-Blind 12-week Trial for Efficacy of Capre on Hypertriglyceridemia [TRIFECTA]) Effects of the Cholesteryl Ester Transfer Protein Inhibitor Dalcetrapib in Patients With Recent Acute Coronary Syndrome Cell-Based Therapies for Myocardial Regeneration Results of the Swiss Multicenter Intracoronary Stem Cells Study in Acute Myocardial Infarction (Swiss Ami) Trial The ALCADIA (Autologous Human Cardiac-Derived Stem Cell to Treat Ischemic Cardiomyopathy) Trial The Effect of Timing of Stem Cell Delivery Following Acute Myocardial Infarction: The NHLBI and CCTRN TIME Trial Randomized Comparison of Allogeneic Versus Autologous Mesenchymal Stem Cells in Patients With Ischemic Cardiomyopathy Effect of Cardiac Stem Cells in Patients with Ischemic Cardiomyopathy: Interim Results of the SCIPIO Trial up to Two Years After Therapy Management of LV Dysfunction: Devices and Drugs MADIT Randomized Trial to Reduce Inappropriate Therapy (MADIT-RIT) Biventricular Versus Right Ventricular Pacing in Patients With Left Ventricular Dysfunction and Atrioventricular Block (BLOCK HF Study) Pilot Trial of Two Levels of Hypothermia in Comatose Survivors From Out-of-Hospital Cardiac Arrest The RELAXin in Acute Heart Failure (RELAX-AHF-1) Trial Cardiorenal Rescue Study in Acute Decompensated Heart Failure: Results of CARRESS-HF, for the Heart Failure Clinical Research Network

Clinical Science: Special Report sessions Prevention and Treatment of Ischemic Heart Disease: Novel Approaches Low Dose Colchicine for Secondary Prevention of Cardiovascular Disease [LoDoCo]: A Randomized Controlled Trial Results of the Responses of Myocardial Ischemia to Escitalopram Treatment Trial Safety and Efficacy of Losmapimod in Non-ST-Segment Elevation Acute Myocardial Infarction: Results of the SOLSTICE Phase 2 Randomized Trial EnligHTN™I, First-in-Man Multi-Center Study of a Novel Multi-Electrode Renal Denervation Catheter in Patients with Drug-Resistant Hypertension New Insights into Management of Common Cardiovascular Disorders A Randomized Trial to Assess Catheter Ablation Versus Rate Control in the Management of Persistent Atrial Fibrillation in Chronic Heart Failure Pulmonary Antrum Radial-Linear Ablation of Paroxysmal Atrial Fibrillation: First-in-Human Multicenter Clinical Outcome Prospective Randomized Study to Assess the Efficacy of Site and Rate of Atrial Pacing on Long-Term Progression of Atrial Fibrillation in Sick Sinus Syndrome--Septal Pacing for Atrial Fibrillation Suppression Evaluation [SAFE] Study Left Ventricular Systolic Dysfunction Associated With Pulmonary Hypertension Riociguat Trial (LEPHT) Sildenafil and Diastolic Dysfunction After Acute Myocardial Infarction in Patients With Preserved Ejection Fraction--A Prospective, Double-Blind Placebo-Controlled Randomized Trial (SIDAMI) Emerging Therapeutics for Diabetes and Dyslipidemia Impact of LX4211, a Dual Inhibitor of Sodium Glucose Transporter 1 and 2 on Cardiovascular Risk Factors in Type 2 Diabetes LAPLACE-TIMI 57 Primary Results Efficacy and Safety of a Fully Human Monoclonal Antibody Against PCSK9 as Monotherapy for Hypercholesterolemia: Results From the MENDEL Study, a Global Phase 2 Trial of AMG 145 AMG 145, a Fully Human Monoclonal Antibody Against Proprotein Convertase Subtilisin Kexin type 9 (PCSK9), Facilitates Achievement of NCEP LDL-Cholesterol Goals in High-Risk Patients Valvular Heart Disease, PAD, Atrial Fibrillation: International Perspectives Mitral Valve Annuloplasty Plus CABG Versus CABG Only in Moderate Functional Ischemic Mitral Regurgitation: Final Results of the Randomized Ischemic Mitral Evaluation (RIME) Trial EndOVascular Treatment for Infra-Inguinal Vessel, in Patients With Critical Limb Sichemia (olive) Registry in Japan Management and One Year Outcome of Atrial Fibrillation in Middle Eastern Cohort Enrolled in the Observational Gulf Survey of Atrial Fibrillation Events (Gulf SAFE) Clinical Implications of Device-Detected Atrial Tachyarrhythmias: Results From the Registry of Atrial Tachycardia and Atrial Fibrillation Episodes in the Cardiac Rhythm Management Device Population (RATE) Antithrombotic Treatments and Associated Outcomes in Patients With Atrial Fibrillation: The Global Anticoagulant Registry in the FIELD (GARFIELD) Randomized Comparison of the Effects of Two Doses of Dabigatran Etexilate on Clinical Outcomes Over 4.3 Years: Results of the Rely-able Double-Blind Randomized Trial Watch all six Late-Breaking Clinical Trial sessions live at your convenience and from anywhere in the world. The AHA will live stream 2012's LBCT Sessions I through VI. View these ground-breaking presentations from the convenience of your personal computer--as if you were with us in Los Angeles. Sessions will be available for purchase beginning Oct. 24. Only $79 per session for AHA professional members. $99 per session for all others. If you would like to be notified when LBCT Live is available for purchase, contact us today and ask to be added to the LBCT Live site alert.